UMDNJ, Cepheid Win $1.3M for Blood-Based Biothreat Tests; Cepheid to Use Tech in MDx Products
March 15, 2012
UMDNJ, Cepheid Win $1.3M for Blood-Based Biothreat Tests; Cepheid to Use Tech in MDx Products
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Cepheid Plans 1,000-Target PCR, Protein Detection, FFPE Analysis, Other Upgrades to GeneXpert
September 27, 2012 / PCR Insider - Cepheid's TB, Drug-Resistance Assay Shines as POC Test in Developing World
September 2, 2010 / PCR Insider - Q&A: Johns Hopkins' David Dowdy on a Comparative Effectiveness Study of Cepheid's Xpert TB Test
May 30, 2013 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider